Robert G Schmidt

USPTO Granted Patents = 23 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 13)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 8.8

ph-index = 5

Forward Citations = 79(Granted Patents)

Location History:

Waukegan, IL (US) (2005 - 2013)
Antioch, IL (US) (2013 - 2019)

Company Filing History:

13 out of 4,177

Abbott Laboratories Corporation

Years Active: 2005-2019

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10266532 - Tricyclic modulators of TNF signaling (2019-04-23),

2. 9012651 - TRPV3 modulators (2015-04-21),

3. 8772500 - TRPV3 modulators (2014-07-08),

4. 8772499 - TRPV3 modulators (2014-07-08),

5. 8609692 - TRPV1 antagonists (2013-12-17),

6. 8604053 - TRPV1 antagonists (2013-12-10),

7. 8487116 - Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2013-07-16),

8. 8440691 - Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof (2013-05-14),

9. 8350083 - Antagonists of the TRPV1 receptor and uses thereof (2013-01-08),

10. 8338603 - TRPV1 antagonists (2012-12-25),

11. 8247413 - Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2012-08-21),

12. 8232309 - Prodrugs of compounds that inhibit TRPV1 receptor (2012-07-31),

13. 8084616 - TRPV1 antagonists (2011-12-27),

14. 8071762 - Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2011-12-06),

15. 8030504 - Antagonists of the TRPV1 receptor and uses thereof (2011-10-04),

Title: **A Spotlight on Robert G Schmidt: Innovator and Patent Holder**

Introduction

Robert G Schmidt, an accomplished inventor based in Waukegan, IL, has made significant contributions to the field of pharmaceutical innovations with an impressive portfolio of 23 patents. His work primarily focuses on developing novel compounds for treating a range of immunological and oncological conditions, demonstrating his commitment to advancement in healthcare.

Latest Patents

Among his latest patents are two notable inventions:

1. **Tricyclic Modulators of TNF Signaling** - This invention introduces tricyclic heterocyclic compounds, which include pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and various stereoisomers. These compounds have potential applications in treating immunological and oncological conditions, highlighting their therapeutic significance.

2. **TRPV3 Modulators** - This patent outlines modulators of TRPV3, characterized by a specific formula. The invention includes compositions comprised of these compounds and presents methods for treating various conditions through their application.

Career Highlights

Robert's professional journey includes notable tenures at esteemed companies such as Abbott Laboratories and AbbVie Inc. His work at these organizations has played a crucial role in advancing drug development and innovation within the pharmaceutical industry.

Collaborations

Throughout his career, Robert has worked alongside talented individuals, including colleagues Arthur Gomtsyan and Erol K Bayburt. These collaborations showcase the importance of teamwork in driving innovation and achieving successful outcomes in research and development.

Conclusion

Robert G Schmidt stands as a prominent figure in the world of pharmaceutical innovations. With his extensive patent portfolio and impactful collaborations, he continues to contribute to the advancement of medical science, ultimately benefiting numerous patients and the healthcare industry. His dedication to finding new solutions underscores the vital role inventors play in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.